牛牛AI助理已提取核心訊息
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in Adial Pharmaceuticals, Inc. This stake amounts to 166,972 shares in the company's common stock. The filing indicates that Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Consequently, both Armistice Capital and Steven Boyd may be deemed to beneficially own the securities of Adial Pharmaceuticals held by the Master Fund. The Master Fund, however, disclaims beneficial ownership of these securities due to its Investment Management Agreement with Armistice Capital, which limits its ability to vote or dispose...Show More
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in Adial Pharmaceuticals, Inc. This stake amounts to 166,972 shares in the company's common stock. The filing indicates that Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Consequently, both Armistice Capital and Steven Boyd may be deemed to beneficially own the securities of Adial Pharmaceuticals held by the Master Fund. The Master Fund, however, disclaims beneficial ownership of these securities due to its Investment Management Agreement with Armistice Capital, which limits its ability to vote or dispose of the securities. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain investment advisers and parent holding companies. The report emphasizes that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Adial Pharmaceuticals.
2023年12月31日，停戰資本有限責任公司及其管理成員史蒂芬·博伊德向美國證券交易委員會提交了附表13G，披露了阿迪爾製藥公司9.99％的所有權，該股份相當於該公司普通股的166,972股。該文件顯示，作爲停戰資本主基金有限公司的投資經理，停戰資本對主基金持有的證券行使投票權和投資權。因此，停戰資本和史蒂芬·博伊德都可能被視爲受益擁有主基金持有的Adial Pharmicals的證券。但是，主基金宣佈放棄對這些證券的實益所有權，因爲其與Armistice Capital簽訂了投資管理協議，這限制了其投票或處置證券的能力。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，該規則適用於某些投資顧問和母控股公司。該報告強調，這些股票是在正常業務過程中收購的，不是爲了改變或影響Adial Pharmicals的控制權。
2023年12月31日，停戰資本有限責任公司及其管理成員史蒂芬·博伊德向美國證券交易委員會提交了附表13G，披露了阿迪爾製藥公司9.99％的所有權，該股份相當於該公司普通股的166,972股。該文件顯示，作爲停戰資本主基金有限公司的投資經理，停戰資本對主基金持有的證券行使投票權和投資權。因此，停戰資本和史蒂芬·博伊德都可能被視爲受益擁有主基金持有的Adial Pharmicals的證券。但是，主基金宣佈放棄對這些證券的實益所有權，因爲其與Armistice Capital簽訂了投資管理協議，這限制了其投票或處置證券的能力。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，該規則適用於某些投資顧問和母控股公司。該報告強調，這些股票是在正常業務過程中收購的，不是爲了改變或影響Adial Pharmicals的控制權。
有用
沒用
